Clinical Trial

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Name: To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07454187)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-11

Trial Details

NCT Number	NCT07454187
Lead Sponsor	Hangzhou Sumgen Biotech Co., Ltd.
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	40 participants
Start Date	2026-04-16
Primary Completion	2027-09-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-10